These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15312916)

  • 1. Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs.
    Davis M; Rhodes T; Martin A
    Soc Sci Med; 2004 Nov; 59(9):1807-18. PubMed ID: 15312916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadening discussions of "safe" in hepatitis C prevention: a close-up of swabbing in an analysis of video recordings of injecting practice.
    Treloar C; Laybutt B; Jauncey M; van Beek I; Lodge M; Malpas G; Carruthers S
    Int J Drug Policy; 2008 Feb; 19(1):59-65. PubMed ID: 18312820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hygiene and uncertainty in qualitative accounts of hepatitis C transmission among drug injectors in Serbia.
    Rhodes T; Zikic B; Prodanović A; Kuneski E; Bernays S
    Soc Sci Med; 2008 Mar; 66(6):1437-47. PubMed ID: 18201809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty.
    Rhodes T; Davis M; Judd A
    Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'There is no profile it is just everyone': the challenge of targeting hepatitis C education and prevention messages to the diversity of current and future injecting drug users.
    Ellard J
    Int J Drug Policy; 2007 May; 18(3):225-34. PubMed ID: 17689369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis.
    Rhodes T; Treloar C
    Addiction; 2008 Oct; 103(10):1593-603. PubMed ID: 18821870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everybody's got it, but...: situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada.
    Wozniak L; Prakash M; Taylor M; Wild TC
    Int J Drug Policy; 2007 Oct; 18(5):388-96. PubMed ID: 17854727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
    Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention.
    Koester S; Glanz J; Barón A
    AIDS Behav; 2005 Mar; 9(1):27-39. PubMed ID: 15812611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troubling biographical disruption: narratives of unconcern about hepatitis C diagnosis.
    Harris M
    Sociol Health Illn; 2009 Nov; 31(7):1028-42. PubMed ID: 19659739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility.
    Kerr T; Small W; Moore D; Wood E
    Int J Drug Policy; 2007 Jan; 18(1):37-45. PubMed ID: 17689342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States.
    Semaan S; Fleming P; Worrell C; Stolp H; Baack B; Miller M
    Drug Alcohol Depend; 2011 Nov; 118(2-3):100-10. PubMed ID: 21515001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing hepatitis C: what do positive injectors do?
    Carruthers SJ
    Drug Alcohol Rev; 2005 Mar; 24(2):193-8. PubMed ID: 16076589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
    Hopwood M; Treloar C
    Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public injection settings in Vancouver: physical environment, social context and risk.
    Small W; Rhodes T; Wood E; Kerr T
    Int J Drug Policy; 2007 Jan; 18(1):27-36. PubMed ID: 17689341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
    Hallinan R; Byrne A; Dore GJ
    Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs.
    Harris M; Rhodes T
    Addiction; 2012 Jun; 107(6):1090-6. PubMed ID: 22151433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users.
    Garfein RS; Golub ET; Greenberg AE; Hagan H; Hanson DL; Hudson SM; Kapadia F; Latka MH; Ouellet LJ; Purcell DW; Strathdee SA; Thiede H;
    AIDS; 2007 Sep; 21(14):1923-32. PubMed ID: 17721100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The depiction of stigmatization in research about hepatitis C.
    Paterson BL; Backmund M; Hirsch G; Yim C
    Int J Drug Policy; 2007 Oct; 18(5):364-73. PubMed ID: 17854724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Fitness for duty": social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs.
    Treloar C; Byron P; McCann P; Maher L
    Vaccine; 2010 Jul; 28(32):5228-36. PubMed ID: 20538093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.